Carbetapentane Citrate
This is the citrate salt form of carbetapentane, sharing its antitussive properties to suppress nonproductive coughing. The salt formulation aids in the stability and oral bioavailability of the active compound. It is commonly included in multi-ingredient cough and cold preparations.
Masse moléculaire
525,6000 g/mol
TPSA
171,00 Ų
Mécanisme d'action
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Structure 2D
Cite this structure
Embed this structure
SMILES
CCN(CC)CCOCCOC(=O)C1(c2ccccc2)CCCC1.O=C(O)CC(O)(CC(=O)O)C(=O)O
InChI
InChI=1S/C20H31NO3.C6H8O7/c1-3-21(4-2)14-15-23-16-17-24-19(22)20(12-8-9-13-20)18-10-6-5-7-11-18;7-3(8)1-6(13,5(11)12)2-4(9)10/h5-7,10-11H,3-4,8-9,12-17H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
Molecular Formula
C26H39NO10
HBD / HBA
4 / 11
Liaisons Rotatives
16
Atomes Lourds
37
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
This is the citrate salt form of carbetapentane, sharing its antitussive properties to suppress nonproductive coughing. The salt formulation aids in the stability and oral bioavailability of the active compound. It is commonly included in multi-ingredient cough and cold preparations.
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Yes, Carbetapentane Citrate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1256696. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 90010. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="carbetapentane-citrate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/carbetapentane-citrate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/carbetapentane-citrate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/carbetapentane-citrate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="carbetapentane-citrate"></drugfyi-drug>